Cavion's Convertible Note Round

Cavion raised a round of funding on November 11, 2015.

Cavion is a privately held clinical stage biotechnology company creating therapies modulating the T-type calcium channel (Cav3) for the treatment of neurological and oncologic diseases. Cavion is co-s…

Articles about Cavion's Convertible Note Round: